ARS Pharmaceuticals, Inc.
SPRYNasdaqCIK 1671858HealthcareFiscal year ends Dec 31
Reports and events: 120 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1316:05 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-349140 |
| 2026-08-1316:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349127 |
| 2026-07-1716:02 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-307773 |
| 2026-07-0716:38 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-297554 |
| 2026-06-2517:01 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-282994 |
| 2026-05-1506:17 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-225142 |
| 2026-05-1506:02 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-225055 |
| 2026-05-1308:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-220671 |
| 2026-04-2916:00 ET | DEF 14A | Proxy statementPeriod 2026-06-24 | 0001193125-26-191433 |
| 2026-03-0906:07 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-097478 |
| 2026-03-0906:01 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-097467 |
| 2025-11-1006:04 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-273111 |
| 2025-11-1006:02 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-273107 |
| 2025-10-0121:19 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-25-000011 |
| 2025-09-2916:15 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-223228 |
| 2025-08-2821:45 ET | 8-K | 8.01 Other events | 0001193125-25-190202 |
| 2025-08-1307:03 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-107618 |
| 2025-08-1307:02 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-107617 |
| 2025-08-0118:06 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001193805-25-001146 |
| 2025-07-2219:38 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001193805-25-001080 |
| 2025-07-0208:24 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001193805-25-000963 |
| 2025-06-2616:15 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-148922 |
| 2025-05-1407:03 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-070900 |
| 2025-05-1407:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-070899 |
| 2025-05-0208:05 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-25-110696 |
| 2025-04-2916:01 ET | DEF 14A | Proxy statementPeriod 2025-06-25 | 0000950170-25-060075 |
| 2025-03-2419:57 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001193805-25-000363 |
| 2025-03-2007:04 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-042320 |
| 2025-03-2007:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-042317 |
| 2025-03-0517:18 ET | 8-K | 8.01 Other events | 0001193125-25-047351 |
| 2025-01-1308:08 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-005014 |
| 2024-12-0616:05 ET | 10-Q/A | Quarterly report, amendedPeriod 2024-09-30 | 0001193125-24-272445 |
| 2024-11-1307:02 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-125924 |
| 2024-11-1307:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125921 |
| 2024-11-1208:01 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-24-255185 |
| 2024-10-1507:02 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-24-237191 |
| 2024-09-2316:15 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-24-223676 |
| 2024-08-1207:59 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-198384 |
| 2024-08-0616:05 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-091776 |
| 2024-08-0616:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-091745 |
| 2024-06-2815:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-172166 |
| 2024-06-2806:46 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-171204 |
| 2024-06-2117:00 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-165812 |
| 2024-06-1720:47 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-162824 |
| 2024-06-1119:18 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-159314 |
| 2024-05-1007:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-135721 |
| 2024-05-0916:12 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-056967 |
| 2024-05-0916:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056934 |
| 2024-04-2616:02 ET | DEF 14A | Proxy statementPeriod 2024-06-20 | 0000950170-24-049071 |
| 2024-03-2916:14 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-041150 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 16:39 ET. Listed shows no prices and gives no investment advice.